The Viral Hepatitis Congress 2012
7–9 September 2012, J.W. Goethe University, Frankfurt, Germany

www.viral-hep.org for more information

Educational 2½-day meeting focusing on the practical treatment of patients with viral hepatitis
Engaging scientific programme with time for interaction and discussion

Abstract deadline
8 June 2012

Early bird registration deadline
23 March 2012 – £375

Standard registration deadline
24 August 2012 – £425

Join us on Facebook: Viral Hep
Follow us on Twitter: @viralhep2012

ACADEMIC SPONSORS:
GOETHE UNIVERSITY FRANKFURT AM MAIN
Weill Cornell Medical College
Friday 7 September

14.30 PRE-EVENT WORKSHOPS
15.30 COFFEE
16.00 INDUSTRY SYMPOSIUM
17.30 Official Opening S Zeuzem (Germany), I Jacobson (USA)
18.00 Key Note Lecture: Hepatitis C Virus R Bartenschlager (Germany)
18.30 Key Note Lecture: Hepatitis B Virus B McMahon (USA)

Saturday 8 September

08.30 PLENARY AND ORAL PAPERS: MANAGEMENT OF HCV IN THE DAA ERA
  Session Chairs: I Jacobson (USA), A Craxi (Italy)
08.30 Managing Treatment-naïve Patients in the DAA Era G Dusheiko (UK)
08.50 Previously Treated Patients: Therapeutic Considerations N Afdhal (USA)
09.10 Side-effect Management: Practical Guidelines M Bourlière (France)
09.30 Resistance: What You Need to Know and Why J-M Pawlotsky (France)
09.50 Oral Paper
10.05 Panel Discussion and Q&A
10.30 COFFEE
11.00 PLENARY: DRUG INTERACTIONS
  Session Chairs: M Manns (Germany), N Afdhal (USA)
11.00 Drug Interactions: A Pathophysiological Review D Back (UK)
11.20 Clinical Management of Drug Interactions in HCV: Case Study Session
  A Craxi (Italy), H Wedemeyer (Germany), X Forns (Spain)
12.00 LUNCH AND POSTERS
13.00 PLENARY: OVERVIEW OF THERAPIES IN DEVELOPMENT FOR HCV
  Session Chairs: S Zeuzem (Germany), H Reesink (The Netherlands)
13.00 Host-targeting Molecules: New Interferons and Cyclophilin Inhibitors
  G Foster (UK)
13.20 New Protease Inhibitors and NS5A Inhibitors with Interferon
  M Sulkowski (USA)
13.40 Nucs and Non-Nucs with Interferon M Fried (USA)
14.00 Interferon-free Regimens D Nelson (USA)
14.20 Quadruple Regimens: Are They Realistic? For Whom Would They Apply?
  J Feld (Canada)
14.40 Panel Discussion and Q&A
15.00 COFFEE
15.30 PLENARY AND ORAL PAPERS: NEW TECHNIQUES FOR DIAGNOSIS
  AND MONITORING
  Session Chairs: M Sulkowski (USA), M Fried (USA)
15.30 Pathophysiological Background and Clinical Applications of IL28B
  M Lagging (Sweden)
15.50 Metabolic Liver Disease in Patients with Viral Hepatitis F Negro (Switzerland)
16.10 Non-invasive Liver Assessment L Castéra (France)
16.30 Oral Paper
16.45 Panel Discussion and Q&A
17.00 INDUSTRY SYMPOSIUM
18.30 INDUSTRY SYMPOSIUM

Sunday 9 September

08.00 INDUSTRY SYMPOSIUM
09.30 PLENARY: PRACTICAL MANAGEMENT OF HEPATITIS B IN 2012 (PART 1)
  Session Chairs: R Esteban (Spain), B McMahon (USA)
09.30 Starting with Nucs P Lampertico (Italy)
09.50 What is the Role of Interferon in 2012? P Marcellin (France)
10.10 Treatment of Hepatitis D M Manns (Germany)
10.30 COFFEE
11.00 PLENARY AND ORAL PAPERS: PRACTICAL MANAGEMENT OF
  HEPATITIS B IN 2012 (PART 2)
  Session Chair: I Jacobson (USA), RS Brown (USA)
11.00 Review of Combination Studies in Hepatitis B J Petersen (Germany)
11.20 Addressing Unmet Needs in Hepatitis B Treatment
  H Janssen (The Netherlands)
11.40 Oral Paper
11.55 Oral Paper
12.10 LUNCH AND POSTERS
13.25 PLENARY AND ORAL PAPERS: HIV CO-INFECTION AND
  TRANSPLANTATION
  Session Chairs: V Soriano (Spain), P Ferenci (Austria)
13.25 Managing Viral Hepatitis and HIV Co-infection in 2012 J Rockstroh (Germany)
13.45 Therapy of Decompensated Cirrhosis: Pre-transplant for HBV and HCV
  T Berg (Germany)
14.05 Focus on Transplantation: Treatment Post-transplant for HBV and HCV
  C Sarrazin (Germany)
14.25 Therapy of Patients with End-stage Renal Disease for HBV and HCV
  P Martin (USA)
14.45 Oral Paper
15.00 COFFEE
15.30 PLENARY AND ORAL PAPERS: NEW ADVANCES IN MANAGING PATIENTS
  WITH HCC AND VIRAL HEPATITIS
  Session Chairs: P Martin (USA), D Nelson (USA)
15.30 Interventional and Surgical Treatment of HCC W Bechstein (Germany)
15.50 Oral Paper
16.05 Medical Treatment of HCC M Colombo (Italy)
16.25 Closing Remarks I Jacobson (USA), S Zeuzem (Germany)